Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
Authors
Keywords
-
Journal
Cancers
Volume 11, Issue 7, Pages 923
Publisher
MDPI AG
Online
2019-07-01
DOI
10.3390/cancers11070923
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?
- (2019) Masayuki Takeda et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
- (2019) Hirokazu Taniguchi et al. Nature Communications
- The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
- (2019) Anna Rachiglio et al. Cancers
- Application of cell-free DNA for genomic tumor profiling: a feasibility study
- (2019) Lise B. Ahlborn et al. Oncotarget
- Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer
- (2019) Gillianne G.Y. Lai et al. JOURNAL OF CLINICAL ONCOLOGY
- MET Copy Number as a Secondary Driver of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in EGFR-Mutant Non–Small-Cell Lung Cancer
- (2019) D. Ross Camidge et al. JOURNAL OF CLINICAL ONCOLOGY
- Protective autophagy decreases osimertinib cytotoxicity through regulation of stem cell-like properties in lung cancer
- (2019) Li Li et al. CANCER LETTERS
- The Roles of MicroRNA in Lung Cancer
- (2019) Kuan-Li Wu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapy
- (2019) Haixia Li et al. LUNG CANCER
- Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
- (2018) Neal I. Lindeman et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Cancer-associated fibroblasts promote epithelial-mesenchymal transition and EGFR-TKI resistance of non-small cell lung cancers via HGF/IGF-1/ANXA2 signaling
- (2018) Yanmei Yi et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations
- (2018) Hidejiro Torigoe et al. CANCER SCIENCE
- Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
- (2018) Zhe Yang et al. CLINICAL CANCER RESEARCH
- Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance
- (2018) Helena A. Yu et al. CLINICAL CANCER RESEARCH
- Clinical Activity of Pan- HER Inhibitors Against HER2 -Mutant Lung Adenocarcinoma
- (2018) In-Jae Oh et al. Clinical Lung Cancer
- Targeting EGFR in Lung Cancer: Current Standards and Developments
- (2018) Asunción Díaz-Serrano et al. DRUGS
- Loss of EGFR confers acquired resistance to AZD9291 in an EGFR-mutant non-small cell lung cancer cell line with an epithelial–mesenchymal transition phenotype
- (2018) Jing Xu et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
- (2018) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update
- (2018) Gregory P. Kalemkerian et al. JOURNAL OF CLINICAL ONCOLOGY
- Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion–Positive Advanced NSCLC
- (2018) Bianca van Veggel et al. Journal of Thoracic Oncology
- Receptor Tyrosine Kinase fusions and BRAF kinase fusions are rare but actionable resistance mechanisms to EGFR tyrosine kinase inhibitors
- (2018) Alexa B. Schrock et al. Journal of Thoracic Oncology
- Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR -Mutated NSCLC
- (2018) Anna Buder et al. Journal of Thoracic Oncology
- Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment
- (2018) Ken Uchibori et al. Journal of Thoracic Oncology
- EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib
- (2018) Yoshihisa Kobayashi et al. Journal of Thoracic Oncology
- A Phase II Study of Pembrolizumab in EGFR-mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve Patients with Advanced NSCLC
- (2018) A. Lisberg et al. Journal of Thoracic Oncology
- High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer
- (2018) Ryo Ariyasu et al. LUNG CANCER
- Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations
- (2018) Biagio Ricciuti et al. LUNG CANCER
- Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy
- (2018) R. Minari et al. LUNG CANCER
- Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities
- (2018) Emily K. Kleczko et al. Molecular Cancer
- TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations
- (2018) Shinichi Hasako et al. MOLECULAR CANCER THERAPEUTICS
- Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer
- (2018) Jacqulyne P. Robichaux et al. NATURE MEDICINE
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model
- (2018) Bo Mi Ku et al. PLoS One
- Afatinib restrains K-RAS–driven lung tumorigenesis
- (2018) Herwig P. Moll et al. Science Translational Medicine
- BIM Deletion Polymorphism Confers Resistance to Osimertinib in EGFR T790M Lung Cancer: a Case Report and Literature Review
- (2018) Xuanzong Li et al. Targeted Oncology
- Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment
- (2018) Jan Nyrop Jakobsen et al. Oncotarget
- Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial–mesenchymal transition is critical in conquering ALK-positive lung cancer
- (2018) Shinji Nakamichi et al. Oncotarget
- T790M mutant copy number quantified via ddPCR predicts outcome after osimertinib treatment in lung cancer
- (2018) Jacky Yu-Chung Li et al. Oncotarget
- Role of long non-coding RNA in drug resistance in non-small cell lung cancer
- (2018) Leirong Wang et al. Thoracic Cancer
- Non-small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report
- (2018) Jing Huang et al. Thoracic Cancer
- Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
- (2018) Chia-Chi Lin et al. Lancet Respiratory Medicine
- Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non–Small Cell Lung Cancer
- (2018) Pedro N. Aguiar et al. JAMA Oncology
- Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non–Small Cell Lung Cancer
- (2018) Shaodong Hong et al. JAMA Oncology
- Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma
- (2018) Chee Khoon Lee et al. JAMA Oncology
- Common Co-activation of AXL and CDCP1 in EGFR -mutation-positive Non-Small Cell Lung Cancer Associated With Poor Prognosis
- (2018) Niki Karachaliou et al. EBioMedicine
- Understanding the biology of HER3 receptor as a therapeutic target in human cancer
- (2018) Hui Lyu et al. Acta Pharmaceutica Sinica B
- Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?
- (2018) Simon Garinet et al. Journal of Clinical Medicine
- Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers
- (2018) Jiacong Wei et al. Cancers
- First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?
- (2018) Ajaz Bulbul et al. Frontiers in Oncology
- Decreased human antigen�R expression confers resistance to�tyrosine kinase inhibitors in epidermal growth factor receptor-mutant lung cancer by inhibiting Bim expression
- (2018) Yunfeng Yao et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- AZD9291 promotes autophagy and inhibits PI3K/Akt pathway in NSCLC cancer cells
- (2018) Zhirui Zhang et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)
- (2018) Yi-Long Wu et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor–Dysregulated Non–Small-Cell Lung Cancer
- (2018) Yi-Long Wu et al. JOURNAL OF CLINICAL ONCOLOGY
- CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Thanyanan Reungwetwattana et al. JOURNAL OF CLINICAL ONCOLOGY
- Have We Really MET a New Target?
- (2018) David Planchard JOURNAL OF CLINICAL ONCOLOGY
- Response to Osimertinib in an EGFR Exon 20 Insertion-Positive Lung Adenocarcinoma
- (2018) Zofia Piotrowska et al. Journal of Thoracic Oncology
- A brief report of transformation from Non-small cell to small cell lung cancer: Molecular and therapeutic characteristics
- (2018) Léonie Ferrer et al. Journal of Thoracic Oncology
- High-throughput sequencing reveals distinct genetic features and clinical implications of NSCLC with de novo and acquired EGFR T790M mutation
- (2018) Panwen Tian et al. LUNG CANCER
- HER kinase inhibition in patients with HER2- and HER3-mutant cancers
- (2018) David M. Hyman et al. NATURE
- Altered conformational landscape and dimerization dependency underpins the activation of EGFR byαC–β4 loop insertion mutations
- (2018) Zheng Ruan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion.
- (2018) Zofia Piotrowska et al. Cancer Discovery
- A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group
- (2018) Tao Jiang et al. Journal of Thoracic Disease
- Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
- (2018) Geoffrey R. Oxnard et al. JAMA Oncology
- Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells
- (2018) Ugo Testa et al. Cancers
- The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response
- (2018) Marzia Del Re et al. BRITISH JOURNAL OF CANCER
- Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-Term follow-up from a pooled analysis of 2 phase 2 studies
- (2018) Myung-Ju Ahn et al. CANCER
- Copenhagen Prospective Personalized Oncology (CoPPO)—Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials
- (2018) Ida Viller Tuxen et al. CLINICAL CANCER RESEARCH
- Epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer
- (2018) Frank Griesinger et al. CURRENT OPINION IN ONCOLOGY
- Targeting the cell signaling pathway Keap1-Nrf2 as a therapeutic strategy for adenocarcinomas of the lung
- (2018) Bo Zhang et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Osimertinib Treatment Was Unsuccessful for Lung Adenocarcinoma with G719S, S768I, and T790M Mutations
- (2018) Shingo Nasu et al. INTERNAL MEDICINE
- EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes
- (2018) Nicolas Marcoux et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case
- (2018) Elisa Roca et al. LUNG CANCER
- Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations
- (2018) Ichidai Tanaka et al. LUNG CANCER
- Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation
- (2018) Jean Bernard Auliac et al. LUNG CANCER
- Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations
- (2018) Hanako Hasegawa et al. LUNG CANCER
- Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro
- (2018) Masaya Nishino et al. LUNG CANCER
- Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study
- (2018) Takamasa Koga et al. LUNG CANCER
- KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR
- (2018) Kaori Nakatani et al. MOLECULAR CANCER THERAPEUTICS
- Dual blockade of EGFR tyrosine kinase using osimertinib and afatinib eradicates EGFR‑mutant Ba/F3 cells
- (2018) Kimio Yonesaka et al. ONCOLOGY REPORTS
- Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib
- (2018) Maximilian J. Hochmair et al. Targeted Oncology
- Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance
- (2018) Daniel de Klerk et al. Cancers
- Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC
- (2018) Youjin Kim et al. Journal of Thoracic Oncology
- Hypoxia, pseudohypoxia and cellular differentiation
- (2017) Sofie Mohlin et al. EXPERIMENTAL CELL RESEARCH
- Unlocking the Mystery of Small-Cell Lung Cancer Transformations in EGFR Mutant Adenocarcinoma
- (2017) Anna F. Farago et al. JOURNAL OF CLINICAL ONCOLOGY
- Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas
- (2017) June-Koo Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting Hypoxia to Improve Non–Small Cell Lung Cancer Outcome
- (2017) Ahmed Salem et al. JNCI-Journal of the National Cancer Institute
- EGFR–Co-Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors
- (2017) Megan B. Barnet et al. Journal of Thoracic Oncology
- Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance
- (2017) Zhen Wang et al. Journal of Thoracic Oncology
- HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib
- (2017) Sai-Hong Ignatius Ou et al. Journal of Thoracic Oncology
- Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France
- (2017) Nicolas Guibert et al. Journal of Thoracic Oncology
- MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values
- (2017) Geun Dong Lee et al. Journal of Thoracic Oncology
- Combination Osimertinib and Gefitinib in C797S and T790M EGFR- Mutated Non–Small Cell Lung Cancer
- (2017) Surein Arulananda et al. Journal of Thoracic Oncology
- ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non–Small Cell Lung Cancer
- (2017) Jessica J. Lin et al. Journal of Thoracic Oncology
- High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer
- (2017) Marcel Wiesweg et al. Journal of Thoracic Oncology
- Dacomitinib versus gefitinib as first-line treatment for patients with EGFR -mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
- (2017) Yi-Long Wu et al. LANCET ONCOLOGY
- Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients
- (2017) Sai-Hong Ignatius Ou et al. LUNG CANCER
- Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3 -mutation, localized transformation to EGFR -mutated SCLC, and acquired T790M EGFR -mutation
- (2017) Eric Santoni-Rugiu et al. LUNG CANCER
- Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET
- (2017) I. Bahce et al. LUNG CANCER
- Mutations in TP53 , PIK3CA , PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes
- (2017) Paul A. VanderLaan et al. LUNG CANCER
- Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC)
- (2017) Catherine Labbé et al. LUNG CANCER
- A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer
- (2017) Hai-Yan Tu et al. LUNG CANCER
- Integrative clinical genomics of metastatic cancer
- (2017) Dan R. Robinson et al. NATURE
- Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
- (2017) Collin M Blakely et al. NATURE GENETICS
- Tracking the Evolution of Non–Small-Cell Lung Cancer
- (2017) Mariam Jamal-Hanjani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- (2017) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of epigenetics in lung cancer heterogeneity and clinical implication
- (2017) Nian Dong et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Erratum: Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2
- (2017) Haikuo Zhang et al. Nature Communications
- Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
- (2017) Kirstine Jacobsen et al. Nature Communications
- Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
- (2017) Emmet J. Jordan et al. Cancer Discovery
- Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations
- (2017) Keita Masuzawa et al. Oncotarget
- Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
- (2017) Jinjing Xia et al. Oncotarget
- Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases
- (2017) Giuseppe Lo Russo et al. Oncotarget
- Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations
- (2017) Stefano Frega et al. Oncotarget
- Targeting Hypoxia to Improve Non–Small Cell Lung Cancer Outcome
- (2017) Ahmed Salem et al. JNCI-Journal of the National Cancer Institute
- EGFR Family Members’ Regulation of Autophagy Is at a Crossroads of Cell Survival and Death in Cancer
- (2017) Elizabeth Henson et al. Cancers
- Drug-sensitive FGFR3 mutations in lung adenocarcinoma
- (2016) P. Chandrani et al. ANNALS OF ONCOLOGY
- Tyrosine kinase receptor EGFR regulates the switch in cancer cells between cell survival and cell death induced by autophagy in hypoxia
- (2016) Yongqiang Chen et al. Autophagy
- Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells
- (2016) Isao Kobayashi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Drug Resistance to EGFR Inhibitors in Lung Cancer
- (2016) Osamu Tetsu et al. CHEMOTHERAPY
- Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2
- (2016) M. Terashima et al. CLINICAL CANCER RESEARCH
- A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial
- (2016) M. Yanagita et al. CLINICAL CANCER RESEARCH
- Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism–Mediated Osimertinib Resistance in EGFR- Mutant Lung Cancer
- (2016) Azusa Tanimoto et al. CLINICAL CANCER RESEARCH
- Impact of TP53 Mutations on Outcome in EGFR -Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors
- (2016) Matteo Canale et al. CLINICAL CANCER RESEARCH
- Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy
- (2016) Paola Ulivi et al. Clinical Lung Cancer
- Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer
- (2016) Geoffrey R. Oxnard et al. JOURNAL OF CLINICAL ONCOLOGY
- Identifying the Appropriate FISH Criteria for Defining MET Copy Number–Driven Lung Adenocarcinoma through Oncogene Overlap Analysis
- (2016) Sinéad A. Noonan et al. Journal of Thoracic Oncology
- S768I Mutation in EGFR in Patients with Lung Cancer
- (2016) Konstantinos Leventakos et al. Journal of Thoracic Oncology
- Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations
- (2016) Alexa B. Schrock et al. Journal of Thoracic Oncology
- Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR -Mutant Lung Cancer Harboring De Novo MET Amplification
- (2016) Justin F. Gainor et al. Journal of Thoracic Oncology
- Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis
- (2016) Li-Yang Chen et al. LUNG CANCER
- Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer
- (2016) Yoshihisa Kobayashi et al. MOLECULAR CANCER THERAPEUTICS
- Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
- (2016) Yong Jia et al. NATURE
- FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling
- (2016) C Daly et al. ONCOGENE
- Genome-wide profiling of long non-coding RNA expression patterns in the EGFR-TKI resistance of lung adenocarcinoma by microarray
- (2016) YING WU et al. ONCOLOGY REPORTS
- Biomarkers along the continuum of care in lung cancer
- (2016) Stefan Holdenrieder SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION
- Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations
- (2016) Guoping Cheng et al. OncoTargets and Therapy
- Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
- (2016) Jun Wang et al. OncoTargets and Therapy
- Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells
- (2016) Michael Ramirez et al. Nature Communications
- Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
- (2016) J. F. Gainor et al. Cancer Discovery
- Genetic alterations and protein expression in combined small cell lung cancers and small cell lung cancers arising from lung adenocarcinomas after therapy with tyrosine kinase inhibitors
- (2016) Xiaohua Shi et al. Oncotarget
- Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations
- (2016) Na-Na Lou et al. Oncotarget
- Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium)
- (2016) Sun Min Lim et al. Oncotarget
- Exon 19 L747P mutation presented as a primary resistance to EGFR-TKI: a case report
- (2016) Yu-Ting Wang et al. Journal of Thoracic Disease
- Prevalence of rareEGFRgene mutations in nonsmall-cell lung cancer: a multicenter study on 3856 Polish Caucasian patients
- (2015) P. Krawczyk et al. ANNALS OF ONCOLOGY
- Lung cancer patients withHER2mutations treated with chemotherapy andHER2-targeted drugs: results from the European EUHER2 cohort
- (2015) J. Mazières et al. ANNALS OF ONCOLOGY
- MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation
- (2015) Rintaro Noro et al. BMC CANCER
- Epidermal Growth Factor Receptor–Mutant Lung Cancer
- (2015) Zofia Piotrowska et al. CANCER JOURNAL
- Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models
- (2015) C. A. Eberlein et al. CANCER RESEARCH
- The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
- (2015) M. J. Niederst et al. CLINICAL CANCER RESEARCH
- EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs
- (2015) Y. Kobayashi et al. CLINICAL CANCER RESEARCH
- The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
- (2015) T. Helsten et al. CLINICAL CANCER RESEARCH
- Predictive efficacy of11C-PD153035 PET imaging for EGFR-tyrosine kinase inhibitor sensitivity in non-small cell lung cancer patients
- (2015) Dong Dai et al. INTERNATIONAL JOURNAL OF CANCER
- Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma
- (2015) Weijing Cai et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy inEGFR-Mutant Lung Cancer: A Meta-Analysis
- (2015) Chee Khoon Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation
- (2015) Shuhang Wang et al. Journal of Hematology & Oncology
- The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression
- (2015) Siyuan Dong et al. Journal of Hematology & Oncology
- Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas
- (2015) Juliana Eng et al. Journal of Thoracic Oncology
- Inhibition of β-Catenin Enhances the Anticancer Effect of Irreversible EGFR-TKI in EGFR-Mutated Non–small-cell Lung Cancer with a T790M Mutation
- (2015) Yosuke Togashi et al. Journal of Thoracic Oncology
- Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met–Amplified Adenocarcinoma of the Lung
- (2015) Martin Frederik Dietrich et al. Journal of Thoracic Oncology
- The 2015 World Health Organization Classification of Lung Tumors
- (2015) William D. Travis et al. Journal of Thoracic Oncology
- Mechanisms of Acquired Resistance to AZD9291
- (2015) Tae Min Kim et al. Journal of Thoracic Oncology
- Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma
- (2015) Zoltan Lohinai et al. Journal of Thoracic Oncology
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations
- (2015) Chao-Hua Chiu et al. Journal of Thoracic Oncology
- Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience
- (2015) Lynette M. Sholl et al. Journal of Thoracic Oncology
- Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
- (2015) James C-H Yang et al. LANCET ONCOLOGY
- Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin
- (2015) Matthew G Oser et al. LANCET ONCOLOGY
- Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: A retrospective analysis in Korea
- (2015) Jin Ho Baek et al. LUNG CANCER
- Comprehensive genomic profiles of small cell lung cancer
- (2015) Julie George et al. NATURE
- Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
- (2015) Kenneth S Thress et al. NATURE MEDICINE
- Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer
- (2015) Lecia V. Sequist et al. NEW ENGLAND JOURNAL OF MEDICINE
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- (2015) Pasi A. Jänne et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activating ERBB4 mutations in non-small cell lung cancer
- (2015) K J Kurppa et al. ONCOGENE
- Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib
- (2015) K Yonesaka et al. ONCOGENE
- Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments
- (2015) Debby D. Wang et al. PLoS One
- Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer
- (2015) Nils D. Arvold et al. TECHNOLOGY IN CANCER RESEARCH & TREATMENT
- Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor
- (2015) Z. Piotrowska et al. Cancer Discovery
- Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer
- (2015) Ningning Cheng et al. Oncotarget
- Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma
- (2015) Emilio Bria et al. Oncotarget
- The BIM deletion polymorphism is a prognostic biomarker of EGFR-TKIs response in NSCLC: A systematic review and meta-analysis
- (2015) Wei Nie et al. Oncotarget
- The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer
- (2015) Kimio Yonesaka et al. Oncotarget
- Molecular profiling of lung adenosquamous carcinoma: hybrid or genuine type?
- (2015) Erik Vassella et al. Oncotarget
- Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients
- (2015) Rui Wang et al. Oncotarget
- Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer
- (2015) Juan Zhou et al. Oncotarget
- Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer
- (2015) Ijeoma Umelo et al. Oncotarget
- BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
- (2015) Niki Karachaliou et al. Scientific Reports
- NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer
- (2015) Collin M. Blakely et al. Cell Reports
- Chloroquine Enhances Gefitinib Cytotoxicity in Gefitinib-Resistant Nonsmall Cell Lung Cancer Cells
- (2015) Mei-Chuan Tang et al. PLoS One
- FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor
- (2015) Koichi Azuma et al. Oncotarget
- Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor
- (2014) J. K. Won et al. ANNALS OF ONCOLOGY
- Treatment with insulin-like growth factor 1 receptor inhibitor reverses hypoxia-induced epithelial–mesenchymal transition in non-small cell lung cancer
- (2014) Fariz Nurwidya et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib
- (2014) Boe S. Sorensen et al. CANCER
- -Catenin Contributes to Lung Tumor Development Induced by EGFR Mutations
- (2014) S. Nakayama et al. CANCER RESEARCH
- Identification of Recurrent FGFR3-TACC3 Fusion Oncogenes from Lung Adenocarcinoma
- (2014) M. Capelletti et al. CLINICAL CANCER RESEARCH
- Lung Cancers with ConcomitantEGFRMutations andALKRearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors Phosphorylation
- (2014) Jin-Ji Yang et al. CLINICAL CANCER RESEARCH
- MET Amplification Status in Therapy-Naive Adeno- and Squamous Cell Carcinomas of the Lung
- (2014) H.-U. Schildhaus et al. CLINICAL CANCER RESEARCH
- The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial
- (2014) C. Costa et al. CLINICAL CANCER RESEARCH
- CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance
- (2014) Kang-Seo Park et al. JOURNAL OF CLINICAL INVESTIGATION
- V843I, a Lung Cancer Predisposing EGFR Mutation, Is Responsible for Resistance to EGFR Tyrosine Kinase Inhibitors
- (2014) Satsuki Matsushima et al. Journal of Thoracic Oncology
- Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q
- (2014) Satoshi Watanabe et al. Journal of Thoracic Oncology
- Small-Cell Lung Cancers in Patients Who Never Smoked Cigarettes
- (2014) Anna M. Varghese et al. Journal of Thoracic Oncology
- Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: Report of a case and review of the literature with demonstration of genes alteration into the same tumor cells
- (2014) Licia Baldi et al. LUNG CANCER
- Comprehensive molecular profiling of lung adenocarcinoma
- (2014) Eric A. Collisson et al. NATURE
- Genomic and molecular characterization of esophageal squamous cell carcinoma
- (2014) De-Chen Lin et al. NATURE GENETICS
- Acquired resistance to TKIs in solid tumours: learning from lung cancer
- (2014) D. Ross Camidge et al. Nature Reviews Clinical Oncology
- Molecular mechanisms of epithelial–mesenchymal transition
- (2014) Samy Lamouille et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Hypoxia Increases Gefitinib-Resistant Lung Cancer Stem Cells through the Activation of Insulin-Like Growth Factor 1 Receptor
- (2014) Akiko Murakami et al. PLoS One
- Alteration in Mir-21/PTEN Expression Modulates Gefitinib Resistance in Non-Small Cell Lung Cancer
- (2014) Hua Shen et al. PLoS One
- Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients
- (2014) Hang Li et al. OncoTargets and Therapy
- Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations
- (2014) Y. Y. Janjigian et al. Cancer Discovery
- Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study
- (2013) J. K. Lee et al. ANNALS OF ONCOLOGY
- Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
- (2013) R. Dienstmann et al. ANNALS OF ONCOLOGY
- EGFR-TKI Resistance Due to BIM Polymorphism Can Be Circumvented in Combination with HDAC Inhibition
- (2013) T. Nakagawa et al. CANCER RESEARCH
- ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer
- (2013) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): A Catalog of Clinically Relevant Cancer Mutations to Enable Genome-Directed Anticancer Therapy
- (2013) P. Yeh et al. CLINICAL CANCER RESEARCH
- Characteristics of Lung Cancers Harboring NRAS Mutations
- (2013) K. Ohashi et al. CLINICAL CANCER RESEARCH
- Frequency of epidermal growth factor receptor mutations in Bangladeshi patients with adenocarcinoma of the lung
- (2013) Shakibur Rahman et al. International Journal of Clinical Oncology
- Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
- (2013) Julien Mazières et al. JOURNAL OF CLINICAL ONCOLOGY
- Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
- (2013) Justin F. Gainor et al. JOURNAL OF CLINICAL ONCOLOGY
- KRAS Mutations as Prognostic and Predictive Markers in Non–Small Cell Lung Cancer
- (2013) Petra Martin et al. Journal of Thoracic Oncology
- A dramatic lung cancer course in a patient with a rare EGFR germline mutation exon 21 V843I: Is EGFR TKI resistance predictable?
- (2013) Nadine Demierre et al. LUNG CANCER
- Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer
- (2013) Yuan-yuan Li et al. LUNG CANCER
- MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer
- (2013) Bing Li et al. LUNG CANCER
- Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC
- (2013) Hideki Terai et al. MOLECULAR CANCER RESEARCH
- Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
- (2013) H. Yasuda et al. Science Translational Medicine
- Patients harboring epidermal growth factor receptor (EGFR) double mutations had a lower objective response rate than those with a single mutation in non-small cell lung cancer when treated with EGFR-tyrosine kinase inhibitors
- (2013) Zhigang Wei et al. Thoracic Cancer
- EGFR tyrosine kinase inhibition induces autophagy in cancer cells
- (2012) Christopher Fung et al. CANCER BIOLOGY & THERAPY
- Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations
- (2012) V. Ludovini et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers
- (2012) Ramaswamy Govindan et al. CELL
- Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
- (2012) Marcin Imielinski et al. CELL
- Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations
- (2012) N. Rekhtman et al. CLINICAL CANCER RESEARCH
- Gefitinib Enhances Cytotoxicities of Antimicrotubule Agents in Non–Small-Cell Lung Cancer Cells Exhibiting No Sensitizing Epidermal Growth Factor Receptor Mutation
- (2012) Chun-Ming Tsai et al. Journal of Thoracic Oncology
- Clinicopathological Characteristics of 11 NSCLC Patients with EGFR-Exon 20 Mutations
- (2012) Marius Lund-Iversen et al. Journal of Thoracic Oncology
- Highly Sensitive Detection of EGFR T790M Mutation Using Colony Hybridization Predicts Favorable Prognosis of Patients with Lung Cancer Harboring Activating EGFR Mutation
- (2012) Yoshihiko Fujita et al. Journal of Thoracic Oncology
- Genetic heterogeneity and cancer drug resistance
- (2012) Nicholas C Turner et al. LANCET ONCOLOGY
- Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu
- (2012) J. De Grève et al. LUNG CANCER
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
- (2012) Zhenfeng Zhang et al. NATURE GENETICS
- A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer
- (2012) King Pan Ng et al. NATURE MEDICINE
- HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation
- (2012) Ken Takezawa et al. Cancer Discovery
- p53 Modulates Acquired Resistance to EGFR Inhibitors and Radiation
- (2011) S. Huang et al. CANCER RESEARCH
- MicroRNA-205 Inhibits Src-Mediated Oncogenic Pathways in Renal Cancer
- (2011) S. Majid et al. CANCER RESEARCH
- EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma
- (2011) M. He et al. CLINICAL CANCER RESEARCH
- Effectiveness of Tyrosine Kinase Inhibitors on "Uncommon" Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non-Small Cell Lung Cancer
- (2011) J.-Y. Wu et al. CLINICAL CANCER RESEARCH
- Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort
- (2011) Seiji Yano et al. Journal of Thoracic Oncology
- FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR
- (2011) Trever G. Bivona et al. NATURE
- EGFR and MET receptor tyrosine kinase–altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers
- (2011) Michela Garofalo et al. NATURE MEDICINE
- EGFR Tyrosine Kinase Inhibitors Activate Autophagy as a Cytoprotective Response in Human Lung Cancer Cells
- (2011) Weidong Han et al. PLoS One
- BIM Expression in Treatment-Naive Cancers Predicts Responsiveness to Kinase Inhibitors
- (2011) A. C. Faber et al. Cancer Discovery
- Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
- (2011) Peter S. Hammerman et al. Cancer Discovery
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
- (2010) Alexa B. Turke et al. CANCER CELL
- Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib
- (2009) Kohji Noguchi et al. CANCER SCIENCE
- Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer
- (2009) David Jackman et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Differential Responses to Erlotinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Cancers With Acquired Resistance to Gefitinib Carrying the L747S or T790M Secondary Mutations
- (2008) Daniel B. Costa et al. JOURNAL OF CLINICAL ONCOLOGY
- The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1
- (2008) Philip A. Gregory et al. NATURE CELL BIOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started